Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
Pharmacology Research & Perspectives
|
December 7, 2018
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs
Agnès Poirier, Marla Weetall, Katja Heinig, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
October 8, 2021
Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the <i>SMN2</i> mRNA Splicing Modifier Risdiplam
Stephen Fowler, Andreas Brink, Yumi Cleary, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 20, 2021
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
Olha Holubovska, Denisa Bojkova, Stefano Elli, et al.
Annals of Clinical and Translational Neurology
|
November 24, 2020
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
Robert C Sergott, Giulia M Amorelli, Giovanni Baranello, et al.
Nucleic Acid Therapeutics
|
May 30, 2025
Developmental and Reproductive Toxicity Testing Strategies for Oligonucleotides: A Workshop Proceedings
Bethany R Hannas, Sara M Bender, Eileen Blasi, et al.
Journal of Medicinal Chemistry
|
June 15, 2016
Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy
Hasane Ratni, Gary M Karp, Marla Weetall, et al.
Journal of Medicinal Chemistry
|
July 26, 2018
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Hasane Ratni, Martin Ebeling, John Baird, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
Pharmacology Research & Perspectives
|
December 7, 2018
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs
Agnès Poirier, Marla Weetall, Katja Heinig, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
October 8, 2021
Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the <i>SMN2</i> mRNA Splicing Modifier Risdiplam
Stephen Fowler, Andreas Brink, Yumi Cleary, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 20, 2021
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
Olha Holubovska, Denisa Bojkova, Stefano Elli, et al.
Annals of Clinical and Translational Neurology
|
November 24, 2020
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
Robert C Sergott, Giulia M Amorelli, Giovanni Baranello, et al.
Nucleic Acid Therapeutics
|
May 30, 2025
Developmental and Reproductive Toxicity Testing Strategies for Oligonucleotides: A Workshop Proceedings
Bethany R Hannas, Sara M Bender, Eileen Blasi, et al.
Journal of Medicinal Chemistry
|
June 15, 2016
Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy
Hasane Ratni, Gary M Karp, Marla Weetall, et al.
Journal of Medicinal Chemistry
|
July 26, 2018
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Hasane Ratni, Martin Ebeling, John Baird, et al.
Page
of 3